Amgen: Clinical Trials

122 trials sponsored by Amgen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

93 completed, 11 terminated, 7 unknown, 6 active not recruiting. 122 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4122Completed 93, Terminated 11, Unknown 7, Active not recruiting 6, Withdrawn 3, Not yet recruiting 1, Recruiting 1

Follow Amgen: new trials by email

Trials (filtered) newest first · largest first

All 122 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia
Phase 4Not yet recruitingAmgen3082027-01-312026-09-21
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Prolia® - Glucocorticoid-induced Osteoporosis
Phase 4Active not recruitingAmgen1022025-05-242026-05-27
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
Prolia - Osteoporosis
Phase 4Active not recruitingAmgen1022024-08-062026-02-12
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder
Phase 4Active not recruitingAmgen322024-04-022025-11-21
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
Pegloticase, Methotrexate - Gout
Phase 4CompletedAmgen3062024-03-182026-09-17
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Avacopan, Placebo, Standard of Care - Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 4RecruitingAmgen3002024-02-072026-11-13
Rivaroxaban Sotorasib Interaction Study
Rivaroxaban 20mg, Sotorasib 960mg - Drug Drug Interaction Study
Phase 4CompletedRadboud University Medical Center212023-11-092024-04-30
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Romosozumab - Postmenopausal Osteoporosis
Phase 4CompletedAmgen1002023-10-302026-10-21
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
XGEVA® - Giant Cell Tumor of Bone
Phase 4Active not recruitingAmgen362023-08-172025-10-01
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Evolocumab, Routine Lipid Management - Cardiovascular Disease, Myocardial Infarction
Phase 4Active not recruitingAmgen60192022-10-262026-11-09
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
Evolocumab 140 MG/ML, Standard of care (SOC) - STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Phase 4Active not recruitingAssistance Publique - Hôpitaux de Paris21662021-09-292026-04-13
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
Teprotumumab, Placebo - Thyroid Eye Disease
Phase 4CompletedAmgen3132021-09-162026-08-21
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
TEPEZZA, Placebo - Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Phase 4CompletedAmgen622021-09-022024-07-01
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS) - B-precursor Acute Lymphoblastic Leukemia
Phase 4TerminatedAmgen102021-08-262025-05-18
Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
Etanercept, OCT - Psoriasis, Psoriatic Arthritis
Phase 4UnknownOptiSkin Medical102021-08-092022-01-06
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
Erenumab - Migraine
Phase 4CompletedAmgen2402021-06-112024-09-19
Reducing Intracranial atheroSclErosis With Repatha
Repatha - Ischemic Stroke
Phase 4TerminatedUniversity of California, Los Angeles102021-04-232023-03-15
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Pegloticase, Methotrexate (MTX) - Uncontrolled Gout
Phase 4CompletedAmgen112021-03-082024-06-27
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Evolocumab - Hyperlipidemias
Phase 4CompletedBrigham and Women's Hospital812021-02-172026-04-16
Erenumab for Idiosyncratic Facial Pain
Erenumab Prefilled Syringe, Placebo - Facial Pain, Rhinosinusitis
Phase 4CompletedDavid Jang, M.D.292021-02-102024-09-24

Showing 20 of 122. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (15)  ·  Anemia (13)  ·  Psoriasis (13)  ·  Renal Insufficiency, Chronic (12)  ·  Hyperparathyroidism, Secondary (8)  ·  Kidney Diseases (8)  ·  Gout (6)  ·  Migraine Disorders (6)  ·  Osteoporosis (6)  ·  Arthritis (5)  ·  Kidney Failure, Chronic (5)  ·  Arthritis, Psoriatic (4)  ·  Heart Failure (4)  ·  Hypercholesterolemia (4)  ·  Neoplasms (4)

Interventions

Etanercept (28)  ·  evolocumab (13)  ·  Darbepoetin alfa (12)  ·  Methotrexate (10)  ·  Cinacalcet (9)  ·  Denosumab (7)  ·  Pegloticase (7)  ·  erenumab (6)  ·  Ivabradine (4)  ·  apremilast (4)  ·  Standard of Care (3)  ·  Vitamin D (3)  ·  glycerol phenylbutyrate (3)  ·  Epoetin Alfa (2)  ·  Folic Acid (2)

Countries

United States (60)  ·  Canada (18)  ·  Spain (10)  ·  Italy (9)  ·  France (7)  ·  Poland (7)  ·  United Kingdom (7)  ·  Denmark (6)  ·  Germany (6)  ·  Austria (5)  ·  Czechia (5)  ·  Belgium (4)  ·  China (4)  ·  Hungary (4)  ·  India (4)

Top investigators

Leonardo Clavijo, MD, PhD (2)  ·  Robert Bissonnette, MD (2)  ·  Anil K Chandraker, MD (1)  ·  Bente L Langdahl, MD PhD DMSc (1)  ·  Boni E Elewski, MD (1)  ·  Carol A. Wallace, MD (1)  ·  Charlotte B Norager, M.D. (1)  ·  David Jang, MD (1)  ·  Dominick Angiolillo, MD, PhD (1)  ·  Dr Lalit Lakhwani, MD (1)  ·  Eugenia Raichlin, MD (1)  ·  Hannu T Aro, MD, PhD (1)  ·  Henry Ginsberg, MD (1)

Results publications

PMID 18328118, PMID 42825996, PMID 16614237, PMID 17092858, PMID 17373192, PMID 17470434, PMID 17470691, PMID 17500381, PMID 17522247, PMID 17621407, PMID 17666472, PMID 17694552, PMID 17853307, PMID 18165618, PMID 18178780, PMID 18380206, PMID 18576334, PMID 18632499, PMID 19317607, PMID 19365139, PMID 19470620, PMID 20118030, PMID 20943783, PMID 21455550, PMID 21693239, PMID 21797805, PMID 22183975, PMID 22508468, PMID 22730343, PMID 22863242, PMID 24356474, PMID 24786928, PMID 24907147, PMID 25873267, PMID 26361879, PMID 26606398, PMID 27006728, PMID 27188329, PMID 27334320, PMID 27388672, PMID 27483410, PMID 28538380, PMID 28916119, PMID 29462231, PMID 29941047, PMID 30217721, PMID 31651370, PMID 31849542, PMID 32163613, PMID 32217365

NIH funding

2018 (5), 2015 (2), 2019 (2), 2016 (1), 2017 (1), R01AR049762 (1), R01DK032333 (1)